<scp>CD</scp>155, an onco‐immunologic molecule in human tumors

Gao, Jian; Zheng, Qianqian; Xin, Na; Wang, Wei; Zhao, Chenghai

doi:10.1111/cas.13324

Cited by 146 publications

(139 citation statements)

References 59 publications

Supporting

Mentioning

131

Contrasting

Order By: Relevance

“…37 CD226 is upregulated in PVR knock-out mice and anti-PVR antibodies cause T-cell CD226 upregulation in wild-type mice. 38 TIGIT is a coinhibitory receptor expressed on T and NK cells 32,39,40 and, similar to CD226, has NECTIN2 and PVR ligands (Figure 3). 26,27 In a cellline model, TIGIT outcompetes CD226 for the PVR ligand.…”

Section: Figurementioning

confidence: 99%

Identification of targets for prostate cancer immunotherapy

et al. 2019

View full text Add to dashboard Cite

Background We performed profiling of the immune microenvironment of castration‐resistant (CRPC) and castration‐sensitive (CSPC) prostate cancer (PC) in order to identify novel targets for immunotherapy. Methods PD‐L1 and CD3/CD8 immunohistochemistry, PD‐L1/2 fluorescent in situ hybridization, tumor mutation burden, microsatellite instability, and RNA‐seq of 395 immune‐related genes were performed in 19 CRPC and CSPC. Targeted genomic sequencing and fusion analysis were performed in 17 of these specimens. Results CD276, PVR, and NECTIN2 were highly expressed in PC. Comparison of CRPC versus CSPC and primary versus metastatic tissue revealed the differential expression of immunostimulatory, immunosuppressive, and epithelial‐to‐mesenchymal transition (EMT)‐related genes. Unsupervised clustering of differentially expressed genes yielded two final clusters best segregated by CRPC and CSPC status. Conclusion CD276 and the alternative checkpoint inhibition PVR/NECTIN2/CD226/TIGIT pathway emerged as relevant to PC checkpoint inhibition target development.

show abstract

Section: Figurementioning

confidence: 99%

Identification of targets for prostate cancer immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Functionally, CD155 interacts with nectin‐3 to regulate cell adhesion and migration . CD155 is overexpressed in human cancers . It has been reported that CD155 overexpression promotes cell migration and proliferation .…”

Section: Introductionmentioning

confidence: 99%

CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Patients with triple‐negative breast cancer (TNBC) lack molecular targets and have an unfavorable outcome. CD155 is overexpressed in human cancers, but whether it plays a role in TNBC is unexplored. Here we found that CD155 was enriched in both TNBC cell lines and tumor tissues. High CD155 expression was related to poor prognosis of breast cancer patients. CD155 was associated with a mesenchymal phenotype. CD155 knockdown induced a mesenchymal‐epithelial transition in TNBC cells, and suppressed TNBC cell migration, invasion and metastasis in vitro and in vivo. Mechanistically, CD155 cross‐talked with oncogenic IL‐6/Stat3 and TGF‐β/Smad3 pathways. Moreover, CD155 knockdown inhibited TNBC cell growth and survival. Taken together, these data indicate that CD155 contributes to the aggressive behavior of TNBC; targeting CD155 may be beneficial to these patients.

show abstract

“…However, since this balance is often disturbed in the tumor microenvironment and accumulating data suggest that PVR overexpression induces the immune escape of tumor cells, strategies targeting PVR might direct the immune response toward the elimination of tumor cells. 6,[11][12][13][14][15] Based on these findings, several different approaches based on PVR and its interactions are being explored in the field of antitumor therapy and are described in this review.…”

Section: Introductionmentioning

confidence: 99%

Targeting PVR (CD155) and its receptors in anti-tumor therapy

Brlić

Roviš

Cinamon³

et al. 2018

Cell Mol Immunol

122

View full text Add to dashboard Cite

Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.

show abstract

CD155, an onco‐immunologic molecule in human tumors

Cited by 146 publications

References 59 publications

Identification of targets for prostate cancer immunotherapy

Identification of targets for prostate cancer immunotherapy

CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer

Targeting PVR (CD155) and its receptors in anti-tumor therapy

Contact Info

Product

Resources

About